Bank of America
BCAX

Bank of America’s Bicara Therapeutics BCAX Stock Holding History

Bank of America’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.52M Sell
327,989
-7,693
-2% -$132K ﹤0.01% 3267
2025
Q4 		$5.65M Sell
335,682
-120,939
-26% -$2.07M ﹤0.01% 3292
2025
Q3 		$7.21M Buy
456,621
+5,393
+1% +$60.4K ﹤0.01% 3646
2025
Q2 		$4.19M Buy
451,228
+432,818
+2,351% +$5.16M ﹤0.01% 4080
2025
Q1 		$240K Sell
18,410
-15,267
-45% -$203K ﹤0.01% 6076
2024
Q4 		$587K Buy
33,677
+20,336
+152% +$423K ﹤0.01% 5417
2024
Q3 		$340K Buy
+13,341
New +$340K ﹤0.01% 5728

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Bank of America's BCAX Position: Q1 2026 in Review

Bank of America reduced its Bicara Therapeutics (BCAX) stake by 2.3% in Q1 2026, selling an estimated $132K and leaving 327,989 shares worth $6.52M. The position accounts for ﹤0.01% of the portfolio, ranked #3267.

Bank of America first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $7.21M in Q3 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Bank of America held 327,989 shares of Bicara Therapeutics worth $6.52M as of Q1 2026.
  • Bank of America sold 7,693 Bicara Therapeutics shares in Q1 2026, an estimated $132K.
  • Bicara Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3267 holding.
  • Bank of America first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Bank of America's Bicara Therapeutics position peaked at $7.21M in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.